Zacks: Brokerages Expect Cambrex Co. (CBM) Will Announce Quarterly Sales of $184.15 Million

Equities research analysts expect Cambrex Co. (NYSE:CBM) to announce sales of $184.15 million for the current quarter, according to Zacks. Two analysts have provided estimates for Cambrex’s earnings. The highest sales estimate is $185.04 million and the lowest is $183.27 million. Cambrex posted sales of $177.87 million in the same quarter last year, which suggests a positive year over year growth rate of 3.5%. The business is expected to issue its next quarterly earnings results on Thursday, February 8th.

On average, analysts expect that Cambrex will report full year sales of $184.15 million for the current financial year, with estimates ranging from $529.85 million to $537.22 million. For the next financial year, analysts anticipate that the firm will report sales of $542.03 million per share, with estimates ranging from $540.16 million to $543.90 million. Zacks’ sales averages are an average based on a survey of analysts that cover Cambrex.

Cambrex (NYSE:CBM) last issued its quarterly earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.17. The business had revenue of $182.28 million during the quarter, compared to analyst estimates of $181.39 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. Cambrex’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.23 earnings per share.

A number of analysts recently weighed in on the stock. William Blair assumed coverage on shares of Cambrex in a report on Tuesday, January 16th. They issued an “outperform” rating for the company. Zacks Investment Research raised shares of Cambrex from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th. Finally, Craig Hallum reissued a “buy” rating and issued a $60.00 price target (down previously from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $60.00.

Institutional investors have recently modified their holdings of the stock. Advisor Group Inc. grew its holdings in Cambrex by 29.8% during the 2nd quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 615 shares during the period. Visionary Asset Management Inc. acquired a new stake in Cambrex during the 3rd quarter worth $201,000. Trexquant Investment LP acquired a new stake in Cambrex during the 3rd quarter worth $209,000. Flinton Capital Management LLC grew its holdings in Cambrex by 90.9% during the 2nd quarter. Flinton Capital Management LLC now owns 3,570 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 1,700 shares during the period. Finally, Sei Investments Co. grew its holdings in Cambrex by 3,120.9% during the 3rd quarter. Sei Investments Co. now owns 4,155 shares of the biotechnology company’s stock worth $228,000 after acquiring an additional 4,026 shares during the period.

Shares of Cambrex (NYSE:CBM) opened at $51.10 on Friday. The firm has a market cap of $1,730.00, a P/E ratio of 16.75, a P/E/G ratio of 1.24 and a beta of 2.38. Cambrex has a fifty-two week low of $42.55 and a fifty-two week high of $62.95.

TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/09/zacks-brokerages-expect-cambrex-co-cbm-will-announce-quarterly-sales-of-184-15-million.html.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Get a free copy of the Zacks research report on Cambrex (CBM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply